Metraipolis › archive › dc_7d1dd0dafe80
Anifrolumab-A Potential New Systemic Sclerosis Treatment — Europe PMC PMID:41682782
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41682782
- DOI
- 10.3390/jcm15031104
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T10:33:39.421Z
- SHA-256 of the archived text
6eb4fee27f73c67e8779f8c476ea15da3a1fd0edcda51d85eef53a6e2abcd7b5- Stable URL of this page
https://metraipolis.com/documento/dc_7d1dd0dafe80
How to cite
Anifrolumab-A Potential New Systemic Sclerosis Treatment — Europe PMC PMID:41682782 — Europe PMC (en), https://europepmc.org/article/MED/41682782 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7d1dd0dafe80 (Metraipolis archive dc_7d1dd0dafe80, sha256 6eb4fee27f73c67e8779f8c476ea15da3a1fd0edcda51d85eef53a6e2abcd7b5)
BibTeX
@misc{dc7d1dd0dafe80,
title = {Anifrolumab-A Potential New Systemic Sclerosis Treatment — Europe PMC PMID:41682782},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41682782},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7d1dd0dafe80; sha256 6eb4fee27f73c67e8779f8c476ea15da3a1fd0edcda51d85eef53a6e2abcd7b5},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41682782. Agents can read the archived copy with the MCP tool read_document.